PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
暂无分享，去创建一个
H. Lenz | J. Larson | A. Cercek | T. Bekaii-Saab | S. Kopetz | F. Ou | Christina Wu | K. Ng | J. Strickler | R. Corcoran | J. Hubbard | G. Finley | C. Parseghian | F. Sanchez | Sarah Bruggeman